Prospects for a peaceful transfer of (C-Band) power dim.
Clinical data for cholesterol-lowering drug inclisiran looks good.
Last week's bad news continued to weigh on the beleaguered Canadian marijuana stock.
Snapchat will review political ads, possibly earning itself a greater role in the upcoming 2020 elections.
Shares slump after a pair of clinical studies raises new questions about the safety and cost effectiveness of Abiomed's family of heart pumps. Here are the must-know details.
A lower profit outlook for the year didn't go over well with investors.
The small-cap biopharma inked a deal with a major pharmaceutical company, its second in three weeks.
A collaboration with Alphabet's YouTube Music has investors excited.
The clinical-stage biopharmaceutical company announced really great phase 2 results for its lead pipeline candidate.
Yandex appeases the Kremlin with creation of a new veto-armed "public interest foundation."
The company may be in acquisition talks.
Volatility plagues the specialty pharmacy and pharmacy benefit manager.
It was a no-news rally for the cloud software stock.
Quarterly results offer at least reason for hope that the venerable retailer can pull off a turnaround.
The fashion-centric technology platform delivered a quarterly beat and raise.
Shares pop after news breaks that the company is joining an index. Here are the key details for investors.
A prominent hedge fund manager upped his stake in the bankrupt utility.
Intelsat offers to write the FCC a big check...if the FCC will agree to let it earn a profit.
The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.
Earnings astound, and guidance looks pretty great as well.